Sugemalimab
Product Specifications
CAS Number
2256084-03-2
Target
PD-1/PD-L1
Related Pathways
Apoptosis, Immunology/Inflammation, Cell Cycle/Checkpoint
Purity
0.95
Bioactivity
Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1630568 100 µL
FOXO4 (Phospho-Thr451) Polyclonal Conjugated Antibody
Sign In for Pricing
View Details MBS6276563-01 0.1 mL
ATP5H, ID (ATP5H, ATP synthase subunit d, mitochondrial) (MaxLight 490)
Sign In for Pricing
View Details MBS6276563-02 5x 0.1 mL
ATP5H, ID (ATP5H, ATP synthase subunit d, mitochondrial) (MaxLight 490)
Sign In for Pricing
View Details 
JH2876 1 Each
1,4,5,6-Tetrahydroxy-7- (3-methyl-2-buten-1-yl) -9H-xanthen-9-one
Sign In for Pricing
View Details